ÂÜÀòÂÒÂ×

Jonathan Nakashima oversees the company’s R&D initiatives, patient-directed orthotopic PDX (O-PDX) pharmacology studies, and the development and implementation of translational oncology assays for drug development. Dr. Nakashima has more than 15 years of experience developing preclinical oncology models. Under a California Institute for Regenerative Medicine fellowship, he received his doctorate in Medical and Molecular Pharmacology at UCLA, where he developed genetically engineered and patient-derived xenograft models to study cancers of the central and peripheral nervous systems. He continued on with his post-doctoral training in the department of Neurobiology, where he received a Kirschstein National Research Service Award to study the cell-interactions in the brain tumor microenvironment.